The Ministry of Health and Community Protection has warned of a discrepancy in the internal leaflet of "Revlimid (lenalidomide) 5mg, 10mg, 15mg, and 25mg capsules", to treat multiple myeloma, which could expose the drug user to health complications.
In the circular addressed to all health facilities and health-care practitioners in the private health sector, the Ministry stated that a discrepancy was discovered in the Arabic section of the internal bulletin of the product "Revlimid (lenalidomide) 5mg, 10mg, 15mg, and 25mg capsules", used to treat multiple myeloma tumors. , Which may result in damage and health complications to the user.
The ministry said in its circular that the manufacturer of the drug acknowledged that there were typos in the Arabic section only for the updated internal bulletin of the product, which occurred in May 2019, bearing in mind that the English section of the leaflet is correct, free of errors.
Mistakes included the internal bulletin of the drug the usual dose, where I wrote 15 mg instead of 25 mg, and that the bulletin witnessed a reversal of the medication cycle from 21 days to write 12 days by mistake, which included other numbers.
The drug manufacturer confirmed that it will correct the internal bulletin of the product mentioned in the upcoming operations, knowing that the product is registered with the Drug Administration of the Ministry of Health and Community Protection.
The Ministry recommended health care practitioners to note the points of difference in the leaflet during the dispensing of the drug and inform their patients of the need to follow the instructions for use according to the prescription, also called pharmacies to alert patients about the typo in the Arabic translation of the internal bulletin of the product, and contact the treating doctor when necessary, and contact with the ministry if Any side effects occur.